BCR-ABL with an e6a2 fusion in a CML patient diagnosed in blast crisis.
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001483:Base Sequence; D001752:Blast Crisis / Q000235:genetics; D017931:DNA Primers; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000473:pathology* / Q000628:therapy; D008297:Male; D008970:Molecular Weight; D012334:RNA, Neoplasm / Q000235:genetics / Q000302:isolation & purification; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic
D000970:Antineoplastic Agents; D017931:DNA Primers; D012334:RNA, Neoplasm; D016044:Fusion Proteins, bcr-abl